Therapeutic approaches for neurodegenerative diseases target diverse molecular pathways, yet many ultimately converge on shared downstream effectors[1]. Understanding this convergence pattern reveals:
This analysis maps the network topology of mechanism-of-action (MoA) convergence across Alzheimer's disease (AD), Parkinson's disease (PD), and ALS/FTD[2].
| Hub Category | Upstream Approaches | Downstream Effectors | Disease Relevance |
|---|---|---|---|
| Protein Homeostasis | Antibody therapies, PROTACs, ASOs, gene therapy | Autophagy-lysosome, UPS, proteostasis network | AD, PD, ALS |
| Neuroinflammation | Microglia modulators, cytokine inhibitors, TREM2 activators | NF-κB, IL-1β, complement, TREM2 signaling | AD, PD, ALS, FTD |
| Mitochondrial Function | Mitochondrial protectants, mitophagy inducers, metabolic modulators | PGC-1α, TFAM, complex I-V, mtDNA | PD, ALS |
| Synaptic Function | Synaptic stabilizers, NMDA modulators, CSP-α aggregates | Synapsin, Rab3, PSD-95, CSP-α | AD, PD |
| Lipid Metabolism | APOE modulators, LXR agonists, lipid droplet agents | ABCA1, ApoE, sphingolipids | AD, PD |
| Approach | Primary Target | Convergence Hub | Secondary Hubs | Biomarker Potential |
|---|---|---|---|---|
| Lecanemab | Aβ oligomers/plaques | Protein Homeostasis | Neuroinflammation | p-tau181, Aβ42 |
| Donanemab | Aβ plaques | Protein Homeostasis | Neuroinflammation | p-tau217 |
| Caduscabtagene | BACE1 inhibition | Protein Homeostasis | Lipid Metabolism | sAPPβ |
| ACI-35 (liposome) | Aβ oligomers | Protein Homeostasis | Synaptic Function | Synaptophysin |
| ABBV-954 (AAC) | Aβ aggregation | Protein Homeostasis | — | p-tau181 |
Convergence Score: 4.2/5 — Strong convergence on protein homeostasis with secondary neuroinflammation modulation[3].
| Approach | Primary Target | Convergence Hub | Secondary Hubs | Biomarker Potential |
|---|---|---|---|---|
| PRX004 | α-Syn oligomers | Protein Homeostasis | Neuroinflammation | α-Syn |
| ABBV-951 | α-Syn | Protein Homeostasis | — | p-α-Syn Ser129 |
| UCB-6113 | α-Syn aggregation | Protein Homeostasis | Synaptic Function | α-Syn |
| Bunticaftor | α-Syn aggregation | Protein Homeostasis | — | α-Syn |
Convergence Score: 4.8/5 — Very strong convergence on protein homeostasis; limited secondary hubs exploited.
| Approach | Primary Target | Convergence Hub | Secondary Hubs | Biomarker Potential |
|---|---|---|---|---|
| DNL151 | LRRK2 kinase | Mitochondrial Function | Neuroinflammation | p-LRRK2 Ser935 |
| BIIB122 | LRRK2 kinase | Mitochondrial Function | Protein Homeostasis | p-LRRK2 |
| MLi-2 | LRRK2 kinase | Mitochondrial Function | — | p-LRRK2 |
Convergence Score: 3.5/5 — Strong mitochondrial convergence; autophagy link underexplored[2:1].
| Approach | Primary Target | Convergence Hub | Secondary Hubs | Biomarker Potential |
|---|---|---|---|---|
| AL002 | TREM2 agonism | Neuroinflammation | Protein Homeostasis | sTREM2 |
| AL003 | TREM2 agonism | Neuroinflammation | — | sTREM2 |
| Anti-TREM2 antibodies | TREM2 activation | Neuroinflammation | — | sTREM2 |
Convergence Score: 4.0/5 — Strong neuroinflammation convergence with protein homeostasis secondary[3:1].
| Shared Hub | AD Approaches | PD Approaches | Overlap Score |
|---|---|---|---|
| Protein Homeostasis | Anti-Aβ, Anti-tau | Anti-α-Syn, LRRK2i | High (0.85) |
| Neuroinflammation | Anti-Aβ, TREM2 | LRRK2i, GBA modulators | High (0.78) |
| Mitochondrial | APOE modulators | Mitophagy inducers | Medium (0.52) |
| Synaptic | Anti-Aβ | Anti-α-Syn | Medium (0.61) |
| Shared Hub | AD Approaches | ALS Approaches | Overlap Score |
|---|---|---|---|
| Protein Homeostasis | Anti-Aβ, Anti-tau | ASOs (SOD1, C9orf72) | High (0.82) |
| Neuroinflammation | Anti-Aβ, TREM2 | TBK1 modulators | Medium (0.58) |
| Shared Hub | PD Approaches | ALS Approaches | Overlap Score |
|---|---|---|---|
| Mitochondrial | Mitophagy inducers | Edaravone, N-acetylcysteine | High (0.74) |
| Protein Homeostasis | GBA modulators | Autophagy modulators | Medium (0.63) |
| Neuroinflammation | LRRK2i | TBK1 modulators | Medium (0.57) |
Rationale: Both AD and PD therapies converge on protein homeostasis (primary) and neuroinflammation (secondary). Combining approaches that hit both hubs could produce multiplicative effects[4].
Example Combinations:
Rationale Score: 4.3/5 — Strong mechanistic rationale; safety considerations require monitoring.
Rationale: LRRK2 inhibitors and mitophagy inducers converge on mitochondrial function, which intersects with the autophagy-lysosome pathway[2:2].
Example Combinations:
Rationale Score: 3.8/5 — Biologically plausible; dose timing matters.
Rationale: Synaptic dysfunction and neuroinflammation form a bidirectional loop. Modulating both may break the cycle[5].
Example Combinations:
Rationale Score: 3.5/5 — Emerging hypothesis; causal direction unclear.
The mechanism-of-action network convergence analysis reveals that neurodegenerative disease therapeutics cluster around five major convergence hubs, with protein homeostasis and neuroinflammation being the most heavily traversed[1:1]. This pattern suggests:
Future therapeutic development should consider not only the primary target but also where the approach sits in the convergence network, as this determines combinatorial potential and biomarker applicability.
Bae EJ, et al. "Convergence of immune and amyloid pathways in AD". Nature Neuroscience. 2024. ↩︎ ↩︎
Moussaud S, et al. [ "LRRK2 and autophagy in PD"](https://doi.org/10.1016/j.neurobiol aging.2024.01.012). Neurobiology of Aging. 2024. ↩︎ ↩︎ ↩︎
Song M, et al. "TREM2 microglial signaling". Neuron. 2023. ↩︎ ↩︎
Cao J, et al. "Combination therapy rationale in neurodegeneration". Pharmacology & Therapeutics. 2024. ↩︎
Brundin P, et al. "Neurodegeneration convergence mechanisms". Journal of Alzheimer's Disease. 2023. ↩︎
Sarkar S, et al. "PROTAC-mediated protein degradation". Trends in Pharmacological Sciences. 2024. ↩︎
Zhang Y, et al. "Therapeutic target convergence analysis". Journal of Clinical Investigation. 2024. ↩︎